SEC Form 4 · accession 0001213900-26-100506
YD Bio Ltd · YDES
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ethan Shen Ph.D.
Officer — CEO · Director
Period of report
Sep 14, 2026
Accepted (ET)
Sep 16, 2026 · 4:01 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002011674
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Sep 14, 2026 | P | 12,700 | $3.85 | A | 11,258,331 | D | |
| Ordinary SharesF2 | holding | — | — | — | 43,120,858 | I | See Footnotes |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.67 to $3.97, inclusive. The reporting person undertakes to provide to YD Bio Ltd (the "Company"), any security holder of the Company or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Ordinary Shares purchased at each separate price within the range set forth above.
- F2The reported shares are held by YD Biopharma Holding Limited, which is wholly owned by E820N Assets Ltd. (BVI), which is wholly owned by The E820N Trust (the "Trust"). Dr. Shen is the settlor, protector and sole beneficiary of the Trust, and is the beneficial owner of such shares.